Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using a topical hair loss treatment from eSurgery containing finasteride, minoxidil, and tretinoin. The user is seeking recommendations and experiences with this specific product.

The user shared their 5-year hair recovery journey using finasteride, RU58841, dutasteride, minoxidil, and microneedling, noting mixed progress but overall improvement. They regret not starting treatment earlier and recently received positive health feedback from their doctor.

The user is using topical dutasteride, finasteride, minoxidil, and tretinoin but seeing no results or side effects. They also microneedle every two weeks but experience little bleeding, questioning if a thick scalp is preventing treatment effectiveness.

The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.

The user is experiencing white flakes and a greasy look from using a topical solution containing 0.025% finasteride, 8% minoxidil, 0.01% retinoic acid, and 1% hydrocortisone. Suggestions include reducing application frequency, using a brush to clean the scalp, and considering alcohol-free alternatives.

A hair transplant without using finasteride or similar medications may lead to unnatural results and further hair loss. Financially capable individuals are advised to stabilize hair loss with medication before considering a transplant.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

After experiencing hair loss due to alopecia areata following COVID-19 vaccination and infection, the individual saw improvement with steroid treatments and Olumiant. They paused Olumiant during a second COVID-19 infection and expressed concern about potential hair loss flare-ups.

The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.